Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Biophytis ( (BPTSY) ).
Biophytis SA, a clinical-stage biotech focused on age-related diseases, is developing its lead candidate BIO101 for muscular conditions like sarcopenia and for obesity, with late-stage trials poised to begin. The France-based group operates through units in the U.S. and Brazil and is listed on Euronext Growth Paris and the U.S. OTC market, giving it access to both European and American capital markets.
On April 29, 2026, Biophytis announced it would postpone publication of its annual financial statements for the year ended December 31, 2025, after its teams were heavily engaged in closing a €2.015 million refinancing completed in March 2026. The company said it cannot meet the April 30, 2026 legal reporting deadline and now aims to release its audited 2025 accounts by the end of May 2026, a delay that may draw investor attention to its financing needs and internal resource constraints but also underscores recent steps to strengthen its balance sheet.
Spark’s Take on BPTSY Stock
According to Spark, TipRanks’ AI Analyst, BPTSY is a Neutral.
The score is primarily held down by weak financial performance (no revenue, ongoing cash burn, and negative equity), reinforced by bearish technicals with the stock trading below major moving averages. Valuation is also constrained by negative earnings and no dividend support, with only a minor offset from oversold momentum readings.
To see Spark’s full report on BPTSY stock, click here.
More about Biophytis
Biophytis SA is a clinical-stage biotechnology company developing drug candidates for age-related diseases. Its lead small-molecule candidate, BIO101 (20-hydroxyecdysone), targets muscular diseases such as sarcopenia, with a Phase 3 trial ready to start, and metabolic disorders including obesity, with a Phase 2 trial ready to start, serving markets in Europe, the U.S., and Brazil.
Headquartered in Paris with subsidiaries in Cambridge, Massachusetts, and Brazil, Biophytis is listed on Euronext Growth Paris and trades American Depositary Shares on the U.S. OTC market. The company’s pipeline positions it in the growing segment of therapies addressing aging-related conditions, which are attracting increasing interest from both regulators and investors.
Average Trading Volume: 702
Technical Sentiment Signal: Sell
Current Market Cap: $2.57M
See more insights into BPTSY stock on TipRanks’ Stock Analysis page.